Searchable abstracts of presentations at key conferences in endocrinology

ea0058p066 | Diabetes | BSPED2018

Are we getting it right? An evaluation of diabetes transitional service at a district general hospital

Gopalakrishna Anil , Patel Vinod , Hulikere Satish

Introduction: Poorly managed transition could adversely impact upon adjustment to diabetes and potentially result in non-adherence to treatment, loss to follow-up and worsening of health-related outcomes. In our DGH, approximately 20 Young Person (YP) with T1DM get transferred to YP Clinic every year. YP between 17–19 years of age attend a joint clinic before the transfer. The YP Clinic provides a continuity of diabetes care up to the age of 25 years.<p class="abstext...

ea0034p148 | Clinical practice/governance and case reports | SFEBES2014

Diabetes: the forgotten complication of parathyroidectomy

Othonos Nantia , Patel Vinod , Nair Rajiv , Ayre Stephen , Saravanan Ponnusamy

A 64-year-old female presented to the acute medical take with hypercalcaemia. She had a 3 weeks history of polyuria, polydipsia, constipation, intermittent abdominal pain and feeling depressed. She reported weight loss of 3.5 kg over the past 6 months. She denied symptoms of dysphagia, dyspnoea, haemoptysis, haematemesis, or malaena. Her past medical history included anaemia, ischaemic heart disease, chronic obstructive pulmonary disease and uterine prolapse. She was an ex-smo...

ea0015oc21 | Tumours, diabetes, bone | SFEBES2008

Delineating the mechanisms of Visfatin regulation in human AT and the implications of TZD treatment in Type 2 Diabetes

McGee Kirsty , Harte Alison , da Silva Nancy , Creely Steven , Baker Adam , Kusminski Christine , Khanolkar Manish , Evans Marc , Chittari Madhu , Patel Vinod , Boardman Shirine , Kumar Sudhesh , McTernan Philip

Objective: The adipocytokine visfatin, expressed in abdominal adipose tissue (AT) is thought to mimic insulin activity. However, whilst central adiposity is closely related to insulin resistance (IR) and T2DM, visfatinsÂ’ role in the development of these conditions remains unclear.Method: We investigated circulating visfatin levels in non-diabetic (ND) and diabetic (T2DM) subjects and in T2DM patients pre- and post- rosiglitazone (RSG) treatment. We ...